Payment overview · 2025
General Payments
$751.29
27 reported records · 11 companies
Healthcare provider profile · identity verified
Kathryn Blocker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BLAIRSVILLE, GA · NPI 1316960123
Verified facts
What the public records show
CMS Open Payments records show Kathryn Blocker, M.D. received $751.29 in general payments during 2025 across 27 reported records.
Corcept Therapeutics accounted for 29.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $221.85 | 29.5% | 5 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $145.20 | 19.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $85.25 | 11.3% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $54.17 | 7.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.39 | 6.8% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.43 | 6.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.17 | 5.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.70 | 4.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.99 | 4.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.64 | 3.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.50 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $751.29 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $221.85 | 5 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $145.20 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $85.25 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $54.17 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $51.39 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.39 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $49.43 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.17 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.99 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 68 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 95 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 123 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
71 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
95 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 131 |
| Atorvastatin Calcium | Atorvastatin Calcium | 384 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 360 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 338 | 95 |
| Lisinopril | Lisinopril | 269 | 79 |
| Montelukast Sodium | Montelukast Sodium | 250 | 73 |
| Tramadol Hcl | Tramadol Hcl | 233 | 57 |
| Famotidine | Famotidine | 230 | 78 |
| Gabapentin | Gabapentin | 223 | 61 |
| Omeprazole | Omeprazole | 211 | 64 |
| Losartan Potassium | Losartan Potassium | 173 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 53 |
| Alprazolam | Alprazolam | 159 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 51 |
| Meloxicam | Meloxicam | 153 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 43 |
| Trazodone Hcl | Trazodone Hcl | 140 | 45 |
| Metformin Hcl | Metformin Hcl | 136 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 38 |
| Azelastine Hcl | Azelastine Hcl | 129 | 54 |
| Ezetimibe | Ezetimibe | 129 | 47 |
| Ozempic | Semaglutide | 123 | 30 |
| Sertraline Hcl | Sertraline Hcl | 123 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 31 |
| Lorazepam | Lorazepam | 101 | 27 |
| Simvastatin | Simvastatin | 98 | 30 |
| Mounjaro | Tirzepatide | 95 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 29 |
| Furosemide | Furosemide | 93 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 28 |
| Valsartan | Valsartan | 92 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 48 |
| Mirtazapine | Mirtazapine | 89 | 23 |
| Ibuprofen | Ibuprofen | 88 | 22 |
| Allopurinol | Allopurinol | 86 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 21 |
| Bupropion Xl | Bupropion Hcl | 84 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 25 |
| Potassium Chloride | Potassium Chloride | 82 | 33 |
| Atenolol | Atenolol | 75 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 21 |
| Carvedilol | Carvedilol | 72 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 26 |
| Synthroid | Levothyroxine Sodium | 71 | 21 |
| Glipizide | Glipizide | 69 | 17 |
| Prednisone | Prednisone | 69 | 63 |
| Eliquis | Apixaban | 68 | 15 |
| Jardiance | Empagliflozin | 67 | 24 |
| Buspirone Hcl | Buspirone Hcl | 64 | 14 |
| Memantine Hcl | Memantine Hcl | 64 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 16 |
| Januvia | Sitagliptin Phosphate | 58 | 17 |
| Clonazepam | Clonazepam | 57 | 11 |
| Celecoxib | Celecoxib | 56 | 21 |
| Eszopiclone | Eszopiclone | 55 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 38 |
| Finasteride | Finasteride | 54 | 12 |
| Temazepam | Temazepam | 54 | 15 |
| Propranolol Hcl | Propranolol Hcl | 53 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 25 |
| Ondansetron Odt | Ondansetron | 52 | 19 |
| Estradiol | Estradiol | 49 | 19 |
| Glimepiride | Glimepiride | 49 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 14 |
| Benazepril Hcl | Benazepril Hcl | 47 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 11 |
| Chlorthalidone | Chlorthalidone | 44 | 13 |
| Pregabalin | Pregabalin | 44 | 14 |
| Alendronate Sodium | Alendronate Sodium | 43 | 12 |
| Lamotrigine | Lamotrigine | 43 | suppressed |
| Baclofen | Baclofen | 39 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 19 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Progesterone | Progesterone, Micronized | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 26 |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 21 |
| Glipizide Er | Glipizide | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 11 |
| Epinephrine | Epinephrine | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Methylprednisolone | Methylprednisolone | 16 | 14 |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Sumatriptan | Sumatriptan | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $751.29 · 27 records | Corcept Therapeutics | AMVUTTRA, Auvelity, CAPLYTA, ELIQUIS, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, VRAYLAR | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error